The industry has given big bucks to U.S. Rep. Greg Walden, who chairs a powerful congressional committee, but has ignored Rep. Peter DeFazio, who is not on any committees that influence drug legislation.
Oregon’s congressional delegation includes members who are among the most courted by the nation’s pharmaceutical industry, and those who are among the most shunned, a new study shows, as the battle over sky-high U.S. prescription drug prices takes on a greater intensity.
This article is for premium subscribers!
To read further, please sign up for a premium subscription. You can also read more about standard and premium subscriptions here. Your subscription dollars are tax deductible and support the in-depth stories you appreciate from The Lund Report. If you believe you already are a premium subscriber, you are already logged in, and you are getting this message, please contact [email protected] Thanks!
If you are a premium subscriber that is not logged in, please login now.